Isis and Genelabs Collaborate on Efforts For Biological Defense | GenomeWeb

REDWOOD CITY, Calif.--Isis Pharmaceuticals and Genelabs Technologies, both with research grants from the Defense Advanced Research Projects Agency, which encourages drug development to combat pathogens used in biological warfare, entered into a collaborative agreement recently. Because the two companies share an interest in understanding how nucleic acids can be exploited as drug targets, the collaborative effort has the potential to significantly advance both firms' research objectives, they said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.